EPAS1 and polycythemia: Recently, somatic gain‐of‐function mutations in EPAS1 (HIF2A) have been associated with neuroendocrine tumours in the presence of erythrocytosis (Zhuang et al, 2012) and, therefore, it may be advised to screen for these events in individuals with known mutations.